user

Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for Dukes' C colon cancer: No differences in treatment arms that could influence survival outcome.

被引：0
|
作者：
Cassidy, J
Koralewski, P
Husseini, F
Twelves, C
机构：
[1] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[2] Rydygier Mem Hosp, Krakow, Poland
[3] Hop Civils Colmar, Colmar, France
[4] Univ Leeds, Bradford, W Yorkshire, England
[5] Bradford NHS Hosp Trust, Bradford, W Yorkshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：267S / 267S
页数：1
相关论文
共 27 条
  • [1] Post-study treatment does not influence outcome in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
    Borner, M.
    Cassidy, J.
    Cervantes, A.
    Koralewski, P.
    Zaluski, J.
    Schuller, J.
    Husseini, F.
    Teller, S.
    Twelves, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 179 - 179
  • [2] Positive efficacy results of the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
    McKendrick, Joseph
    Cassidy, James
    Van Hazel, Guy
    Twelves, Chris
    Wong, Alfred
    Nowacki, Marek
    Kroning, Hendrik
    Cervantes, Andres
    Herrmann, Richard
    Burris, Howard, III
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 74
  • [3] Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer.
    Twelves, C
    Wong, A
    Nowacki, M
    McKendrick, J
    van Hazel, G
    Douillard, JY
    Díaz-Rubio, E
    Cassidy, J
    Maroun, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 251S - 251S
  • [4] Capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (PTS) with Dukes' C colon cancer: Pharmacoeconomic evaluation of X-act trial data from a Czech perspective
    Jiraskova, Lucia
    Dolezal, Tomas
    ANNALS OF ONCOLOGY, 2006, 17 : 123 - 123
  • [5] Italian economic evaluation of capecitabine (X) vs. bolus 5-FU/LV as adjuvant chemotherapy for patients (pts) with Dukes'c colon cancer
    Di Costanzo, F.
    Sobrero, A.
    Twelves, C.
    Douillard, J.
    Giuliani, G.
    Patel, K.
    Garrison, L.
    Cassidy, J.
    ANNALS OF ONCOLOGY, 2006, 17 : 63 - 63
  • [6] Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer:: the X-ACT trial
    Cassidy, J
    Douillard, Y
    Twelves, C
    McKendrick, JJ
    Scheithauer, W
    Bustová, I
    Johnston, PG
    Lesniewski-Kmak, L
    Jelic, S
    Fountzilas, G
    Coxon, F
    Díaz-Rubio, E
    Maughan, TS
    Malzyner, A
    Bertetto, O
    Beham, A
    Figer, A
    Dufour, P
    Patel, KK
    Cowell, W
    Garrison, LP
    BRITISH JOURNAL OF CANCER, 2006, 94 (08) : 1122 - 1129
  • [7] Capecitabine vs. Bolus 5-FU/LV as adjuvant therapy for patients with Dukes' C colon cancer: Pharmacoeconomic evaluation of X-act trial data from Czech perspective
    Jiraskova, L.
    Dolezal, T.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
  • [8] Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
    J Cassidy
    J-Y Douillard
    C Twelves
    J J McKendrick
    W Scheithauer
    I Bustová
    P G Johnston
    K Lesniewski-Kmak
    S Jelic
    G Fountzilas
    F Coxon
    E Díaz-Rubio
    T S Maughan
    A Malzyner
    O Bertetto
    A Beham
    A Figer
    P Dufour
    K K Patel
    W Cowell
    L P Garrison
    British Journal of Cancer, 2006, 94 : 1122 - 1129
  • [9] Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study):: positive efficacy results of a phase III trial.
    Cassidy, J
    Scheithauer, W
    McKendrick, J
    Kröning, H
    Nowacki, MP
    Seitz, JF
    Twelves, C
    Van Hazel, G
    Wong, A
    Díaz-Rubio, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 247S - 247S
  • [10] Capecitabine (X) versus bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Positive efficacy results of a phase III trial
    Fink, M
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 (09) : 620 - 621
123